Cryoport, Inc. and Mitsubishi Logistics Corporation ("MLC") announced a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan. Cryoport and MLC will partner to create synergistic value by leveraging each other's global logistics networks. The partnership will provide integrated, end-to-end distribution solutions for specialty cell and gene therapies that demand stringent temperature control, track and trace systems and global distribution.

MLC has chosen to adopt Cryoport's unique and proprietary temperature-controlled and traceability solutions to meet the increasing demand for cell and gene therapy supply chain solutions and to strengthen its logistics capabilities. As of June 30, 2021, Cryoport supported 561 clinical trials in regenerative medicine globally, 29 of which are in the APAC region. In addition, a number of therapies supported by Cryoport have recently been approved in the APAC region, including Novartis' commercial therapy KYMRIAH®, which is approved in Japan, Singapore and Australia and Bristol Myers Squibb's commercial therapy BREYANZI®, which was approved in Japan.

Cryoport is continuing to build out its position to support the growing number of commercial therapies in anticipation of the next wave of expected commercial approvals in the APAC region.